In light of these promising preliminary efficacy and safety results, a phase III study evaluating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with ET-resistant HR+, HER2− advanced breast cancer was initiated (NCT06757634; VIKTORIA-2). This evidence concerns the gene CDK4 and breast cancer.